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Photodynamic therapy (PDT) is a rapidly evolving treatment
modality with uses ranging from oncology, cardiovascular disease
to hyperproliferative disorders. PDT relies on the ability of certain
photosensitizing agents, usually porphyrins, to absorb light and
convert this energy into cytotoxic molecules including singlet
oxygen. The therapeutic value of this treatment is defined by the
location of photosensitizer during light treatment.
The initial photosensitizer to enter clinical trials, Photofrin, has
been recently approved for use in the USA, Canada, and abroad for
treatment of solid tumours and new drugs are in various stages of
pre-clinical and clinical development. Benzoporphyrin derivative
monoacid ring A (BPD-MA, verteporfin) is a second generation
photosensitizer that has several favourable characteristics for use
in PDT over Photofrin (Levy, 1994). This agent is chemically pure
and is activated with light at long wavelengths (690 nm) which
allows theoretically for deeper penetration of light into the treat-
ment area. Benzoporphyrin derivative has rapid plasma and tissue
pharmacokinetics and is thus quickly cleared from tissues,
resulting in a diminished period of skin photosensitivity compared
to other drugs including Photofrin (Richter et al, 1990; Levy et al,
1993). A wide range of diseases are under investigation for treat-
ment with PDT using BPD including solid tumours (Richter et al,
1993), choroidal neovascularization (Lin et al, 1994), arthritis
(Chowdary, 1994), HIV therapy (North et al, 1996) and uterine
endometrial ablation (Wyss et al, 1994).
Although the targets for BPD based PDT-induced destruction of
tissue remain largely unresolved, studies by Schmidt-Erfurth et al
(1995) have demonstrated vascular damage leading to blood flow
stasis. The predominance of vascular damage in treated tissues
correlates well with the high serum levels of photosensitizer that
are present at short times after drug injection. Light treatment is
generally given within 3 h of drug injection because of the rapid
pharmacokinetics of BPD in tissue (Richter et al, 1990). Tissue
microvasculature is an important target for PDT using several
photosensitizers (Henderson and Farrell, 1989; Fingar et al, 1992)
and direct damage to cells in the vessel wall including endothelial
cells, and damage to blood components, including platelets, has
been observed (Henderson and Dougherty, 1992).
Experiments were performed to evaluate the relative effective-
ness of PDT using BPD at relatively short and long times after
injection. The time between drug injection and light dose was
varied in attempt to elucidate any differences in treatment efficacy
and tissue selectivity at short intervals when the drug is chiefly in
circulation, versus longer time intervals, when the drug has time to
partition into the cells. Traditionally, solid tumours have been
treated 180 min after injection of 2 mg kg-1 BPD (Allison et al,
1991; Richter et al, 1991); however, non-oncological treatments
for PDT such as neovascular ablation have determined that shorter
intervals between BPD injection and light treatment offered better
vascular uptake of photosensitizer (Haimovici et al, 1997). A goal
of these studies was to determine whether shorter intervals
between injection and light treatment would increase tumour
response.
MATERIALS AND METHODS
Animal model
Male Sprague-Dawley rats (80–100 g, Harlan Sprague–Dawley
Inc., Indianapolis, IN, USA) were obtained at least 1 week before
experimentation and were housed in a temperature-controlled
environment with controlled light/dark cycles. Animals were fed
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standard laboratory chow and water ad libitum. Approval for this
project was obtained from the Animal Care and Use Committee at
the University of Louisville and was in compliance with National
Institute of Health guidelines.
A chondrosarcoma tumour cell line maintained in our labora-
tory was used in these experiments as described previously (Fingar
et al, 1990). For tumour implantation in skin, 0.3 ml (1 ´ 106 cells
ml-1) of tumour cells were injected subcutaneously in the centre of
the right flank for treatment response experiments with a 23 gauge
needle. Tumours were used when they reached a diameter of
6–7 mm which occurred within 3–5 days after implantation. A
separate series of animals were given tumour in both the right and
left flank for experiments of fluorescein dye exclusion after PDT.
For tumour implantation into cremaster muscle, rats (80–120 g)
were anaesthetized with sodium pentobarbital (50 mg kg-1 i.p.).
The right testicle was then pushed into the abdominal cavity and a
lower midline laparatomy was performed under sterile conditions
and the cremaster was gently retracted. A chondrosarcoma suspen-
sion was prepared from donor animals and 0.1 ml (1 ´ 105 cells) of
this suspension was injected into the muscle with a 27 gauge
needle. Tumours were used for experimentation when they had
reached a surface diameter of 2–3 mm and a thickness of 1 mm
(3–4 days after implantation).
Photosensitizer
The animals were given BPD-MA in a liposomal formulation
(obtained as a gift from QLT Phototherapeutics, Vancouver,
Canada) via tail vein injection at a dose of 2 mg kg-1. The lipo-
somal BPD was supplied as a lyophilized powder and was initially
suspended in distilled water to a stock concentration of 1.47 mg
ml-1. This solution was further diluted to 0.39 mg ml-1 using a 5%
dextrose solution and was used within 14 days of preparation.
Drug concentrations were verified by absorbance spectroscopy.
Light treatment
Rats were anaesthetized with 50 mg kg-1 sodium pentobarbital i.p.
and placed on their left side. The right leg was shaved and
depilated, then fixed during light treatment to prevent leg move-
ment. For photosensitizer activation, an Argon-dye laser (Laser
Ionics model 1400-12A, or a Coherent Innova 200, Palo Alto, CA,
USA) and a dye laser (Spectra-Physics model 375b dye laser,
Mountain View, CA, USA) with a fibreoptic light delivery system
and microlens was used to illuminate the treatment field containing
tumour. The wavelength was adjusted to 690 nm and verified by
scanning monochromator (Optometrics model DMC1-02, Aver,
MA, USA). The power density of light was 75 mW cm-2 measured
by a thermopile (Coherent model 210, Auburn, CA, USA) for a
total dose of 150 J cm-2 light (2000 s treatment time).
Histological analysis of vessel damage
Tissue samples of cremaster muscle from animals given light treat-
ment at 5 min, 30 min and 180 min after BPD injection or in sham
controls given light treatment alone were collected for histological
study. Cremaster muscles were fixed in situ by flooding the tissue
with a pre-warmed fixative of 4% buffered formalin containing
0.25% glutaraldehyde. The entire cremaster muscle was then
removed and immersed in the same formalin–glutaraldehyde solu-
tion for 24 h at 4°C. Tissue segments containing pairs of arterioles
and venules were identified and dissected free of surrounding
muscle with the aid of a microscope. Samples were processed in
1% osmium tetroxide, dehydrated, embedded in araldite 502,
polymerized and sectioned at 1 mm. Sections were stained with
toluidine blue before examination.
Cremaster muscle preparation for normal and tumour
microvascular studies
Rats were anaesthetized with sodium pentobarbital (55 mg kg-1,
i.p.) and placed on their backs on a temperature-controlled heating
pad. Rectal temperature was maintained at 37°C and back temper-
ature was monitored with a thermocouple to avoid local over-
heating of the skin. The right cremaster muscle was prepared for
microvascular observations in the manner previously reported
(Fingar et al, 1992). The muscle was slit on the ventral midline and
spread with sutures over a cover glass which was positioned on a
cylindrical pedestal. The cremaster was flooded with saline and
covered with a clear plastic film to prevent drying. Transmitted
light video microscopy was used to visualize normal muscle and
tumour microvasculature. Images were recorded on VHS video-
tape for analysis. Arteriole and venule pairs in normal muscle were
chosen for the study based on their diameter (20–30 mm) and
branching order (fourth order). Vessels in tumour were chosen on
size alone since there was no distinct difference in morphology
between 20 and 30 mm tumour arterioles and venules.
Four to five animals were used in each different experimental
group for measurement of vessel diameters. Red blood cell column
diameter (RBCC diameter) and vessel wall diameter were
measured every 5 min for the 33 min of light treatment. Vessels
were monitored for an additional 60 min at 10-min intervals
following light therapy. The RBCC diameter is a measurement of
the inner lumen of the vessel. Reductions in RBCC diameter
without a change in wall diameter indicate that aggregates have
formed at the inner vessel wall.
Fluorescein exclusion study
Exclusion of fluorescein dye in tumour and surrounding skin was
monitored in animals to determine if vessel stasis had occurred
within 24 h after the completion of PDT treatment and was used
to confirm the results from the cremaster studies. Animals given
BPD were anaesthetized using 50 mg kg-1 sodium pentobarbital
and were given light treatment of 150 J cm-2 to the tumour on the
right flank as described above. The tumour on the left leg in this
series of animals served as a control. Animals were injected i.v.
with 0.3 ml of 10 mg kg-1 sodium fluorescein solution in saline at
either 0 h or 24 h after the completion of light treatment. Animals
were sacrificed after 5 min. The location of fluorescein dye was
monitored by exposing the tissue to ultraviolet light (Spectroline
model MB-100 Westbury, NY, USA). Images in both PDT-treated
and control tumours were recorded on photographic film.
Gray scale analysis
A second set of animals were treated similarly with PDT to the
above exclusion study and were given fluorescein dye either 0 h or
24 h after the completion of light treatment. Both the treated and
control tumours were excised after 5 min and were sandwiched
between two glass microscope slides using a 1 mm spacer to
ensure a uniform thickness of tumour tissue. Fluorescence1704 VH Fingar et al
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microscopy images were recorded on VHS videotape from a Zeiss
20T microscope with a 4´ objective and SIT camera (Hamamatsu
model C2400–08, Bridgewater, NJ, USA). Epi-illumination using
blue light (450-490 nm) was used to stimulate the fluorescein in
the tissue for brief periods (< 5 s) and the resulting images were
recorded. The camera settings were standardized between samples
with a 10 ng ml-1 fluorescein sample. Video images were digitized
at a resolution of 512 ´ 512 pixels and the average gray level in
20 000 pixel area centred on tumour was calculated using a hand-
written image analysis software package. Larger gray level data
indicate greater levels of fluorescein fluorescence. Spatial unifor-
mity of fluorescence intensity in fluorescein test samples was
confirmed for the microscope sample field used for these studies
before each experiment. Linearity between fluorescence intensity
and gray level over the range of fluorescence values obtained in
these studies was verified by imaging fluorescein samples ranging
between 0.01 and 100 ng ml-1 fluorescein. Three replicate images
from PDT-treated animals and controls were taken for gray scale
analysis.
Tumour response monitoring
Animals were monitored for tumour regression and/or regrowth
daily for 14 days and at weekly intervals afterwards for a total of
42 days after light treatment. Tumour cure was defined as animals
with no detectable mass through 42 days. The effect of treatment
on tumour and surrounding normal tissue was recorded.
Statistics
The data were measured at each observation interval (13 points)
during intravital microscopy for wall diameter and RBCC diam-
eter in arterioles, venules and tumour microvasculature. The data
were analysed using repeated measures analysis of variance to
examine for differences in response at each time of treatment.
Where the analysis of variance (ANOVA) showed statistical
significance, least squares means were examined to compare the
individual treatments pairwise. For measurements of fluorescence
and gray scale analysis of tissue, the means from experiments
in 3–4 animals and the corresponding 95% confidence interval
(2 s.e.m.) were calculated. Differences in response between groups
and controls were evaluated by ANOVA.
RESULTS
Alterations in vessel diameter
Acute changes in the diameter of 20–30 mm arterioles and venules
in cremaster muscle and changes in 20–30 mm tumour microvas-
culature were monitored through PDT treatment and for a period
of 60 min after the completion of treatment. Administration of
light doses up to 150 J cm-2 690 nm caused a slight dilation of arte-
rioles early after the initiation of PDT, but this was not statistically
different than controls (Figure 1A). No change in the diameter of
cremaster venules was observed irrespective of the time between
BPD injection and light treatment (Figure 1B). No statistically
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Figure 1 Changes in vessel diameter following PDT with BPD. Animals
were injected with 2 mg kg-1 BPD: 5 min, 30 min, or 180 min before the
initiation of light treatment. Light treatment was 150 J cm-2 690 nm to the
cremaster muscle over the first 33 min of observation. The diameter of the
outside wall of arterioles (A), venules (B), and tumour microvasculature (C)
was measured at selected intervals during light treatment and for an
additional 1 h after the completion of the light treatment. ( •) Five-minute time
point, (n) 30-min time point data, (s) 180-min time point data. Points
represent the mean of 5–11 animals, measured as a percentage of the initial
wall diameter. Bars represent 2 s.e.m.Vascular damage after PDT using BPD 1705
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significant change in tumour microvascular diameter was
observed in animals given treatment at 5 min, 30 min, or 180 min
after BPD injection (Figure 1C).
Alterations in the luminal diameter of microvasculature
The diameter of the flowing column of red blood cells was moni-
tored in the same microvasculature described in the previous
section and represents the effective luminal diameter of the blood
vessels. Significant reductions of up to 50–60% were observed in
animals given PDT 5 min after BPD injection (Figure 2A,B)
(P < 0.05 for arterioles, P < 0.01 for venules). Blood flow stasis
did not occur. Animals treated after longer BPD incubation times
did not exhibit this response in the normal microvasculature.
Complete stasis of blood flow and loss of the vessel lumen was
observed in tumour from animals given light treatment within 30
min of BPD injection (Figure 2C). Vascular stasis occurred within
45 J cm-2 light exposure in animals given treatment at 5 min after
BPD injection. In PDT protocols using 5 and 30 min BPD incuba-
tion times, no reperfusion in the tumour microvasculature was
observed within 1 h after the completion of light treatment
compared to animals in the 180-min protocol group or controls
(P < 0.05). Blood flow stasis was absent in tumour microvascula-
ture when tissues were illuminated 180 min after BPD injection.
Vessel histology
Damage to normal microvasculature in cremaster muscle was
evaluated histologically to determine the cause of reductions in
vessel lumen diameter in the intravital microscopy experiments
(Figure 3A–D). Extensive platelet aggregation and red blood cell
agglutination was observed in tissue samples from animals given
light treatment 5 min after BPD injection (Figure 3B). This
response was diminished in the 30-min treatment group although
foci of platelet aggregates at the vessel wall could still be observed
(Figure 3C). No apparent damage was observed in the 180-min
incubation group compared to controls (Figure 3D).
Fluorescein exclusion
A qualitative assessment of vessel shutdown in subcutaneously
implanted tumour and surrounding tissue was performed using a
fluorescein dye exclusion study. Exclusion of this fluorescent dye
in vessels indicates that vascular stasis has occurred, reductions in
the intensity of dye in tissues correlates with reduced tumour perfu-
sion. When the animals were injected with fluorescein immediately
after light treatment and observed under the ultraviolet light, no
fluorescence was observed in tumour from animals given BPD
either 5 min or 30 min before treatment. Fluorescein was not
excluded in the tumour or the untreated leg or in control animals.
Treatment of animals 180 min after BPD injection did not result in
any exclusion of the fluorescein dye in the tumour area immedi-
ately after PDT which correlates with the cremaster studies. When
assayed 24 h after the completion of PDT treatment, complete dye
exclusion was still observed in the 5 min BPD incubation group;
however, visible reductions in the intensity of fluorescein fluores-
cence were also observed in animals in the 180-min treatment
group indicating that some degree of late vascular damage and/or
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Figure 2 Changes in the RBCC diameter in cremaster muscle
microvasculature after treatment. Animals were injected with 2 mg kg-1 BPD:
5 min, 30 min, or 180 min before light treatment. Light treatment was
150 J cm-2 690 nm to the cremaster muscle over the first 33 min of
observation. The diameter of the column of flowing red blood cells within
arterioles (A), venules (B), and tumour microvasculature (C) was measured
at selected intervals during light treatment and for an additional 1 h after the
completion of the light treatment. (•) Five-minute time point, (n) 30-min time
point data, (s) 180-min time point data. Points represent the mean of 5–11
animals, measured as a percentage of the initial RBCC diameter. Bars
represent 2 s.e.m.1706 VH Fingar et al
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blood flow stasis in these animals occurs. In order to further eval-
uate the effect in this set of animals, the fluorescence signal from
tumour was digitized and gray scale analysis was performed.
Animals given BPD and light 180 min after injection had gray scale
levels for tumour of 107.1 ± 22.4 (mean ± 2 s.e.m.) when assayed
24 h after PDT. This value is statistically less than that for control
tumours given BPD and no light (190.4 ± 16.2, P = 0.0002), indi-
cating a reduction in perfusion in tumour for the PDT-treated
animals at 24 h. The progression of vascular damage in these
treated animals did not result in complete blood flow stasis since
even lower gray levels could be produced in tumour from animals
given light treatment 5 min after BPD injection (74.9 ± 15.8, P =
0.035) where stasis was confirmed by intravital microscopy.
Background gray levels of tumour from animals given no fluores-
cein were 60.7 ± 4.3.
Tumour response
The efficacy of PDT using BPD for the different treatment times of
5 min, 30 min and 180 min after photosensitizer injection was
evaluated using a subcutaneously implanted chondrosarcoma
model (Figure 4). Treatment produced initial regression of tumour
in animals given BPD at each of the dosing protocols, tumours
were flat and apparently necrotic within 48 h of light treatment.
The durability of long-term control of tumour regrowth was
inversely proportional to the time between BPD injection and light
treatment. Regrowth of tumour in certain animals in the 30 min
and 180 min BPD incubation groups was observed after 15 days.
Five percent of the animals treated with 2 mg kg-1 BPD 180 min
prior to 150 J cm-2 were tumour-free after 42 days. Fifty-five
percent of the animals treated with 2 mg kg-1 BPD 30 min before
150 J cm-2 light dose were free of tumour after 42 days. All
animals given light treatment 5 min after BPD injection remained
tumour-free at 42 days post-treatment. There was significant
normal tissue damage and necrosis in the 5-min group, with heavy
oedema and eschar forming 1-day post-treatment. Damage was
extensive in these animals resulting in irreversible damage to
muscle in the treatment field. Tumour destruction was more selec-
tive in animals given light treatment at longer BPD incubation
periods. No eschar or apparent damage to skin or muscle was
observed in animals in the 180-min protocol group. Normal tissue
damage in the 30-min group did occur, but this was not as exten-
sive as in the 5-min group.
DISCUSSION
The relative effect of PDT using BPD-MA in different dosing
regimens on damage to tumour and normal microvasculature was
evaluated and correlated with tumour regression.
AB
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Figure 3 Histological studies. Animals were injected with 2 mg kg-1 BPD i.v. and given light treatment after either 5 min, 30 min or 180 min. Light treatment was
150 J cm-2 690 nm to the cremaster muscle. Tissue samples containing pairs of arteriole and venules were collected 1 h after the completion of the light
treatment. (A) Sham control, 675 ´ magnification. (B) Animals given light treatment 5 min after BPD injection (800 ´ magnification). (C) Animals given light
treatment 30 min after BPD injection (475 ´ magnification). (D) Animals given light treatment 180 min after BPD injection (530 ´ magnification). In Figures,
arrows indicate the location of platelet aggregation, bar represents 20 mmVascular damage after PDT using BPD 1707
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An acute vascular reaction to PDT was found in microvascula-
ture during intravital microscopy and the magnitude of this event
was greatest when light treatment was delivered at short times
after BPD injection. At short, 5 min, incubation times, this
response was characterized by reductions in the luminal diameter
of microvasculature due to the formation of platelet aggregates at
the vessel wall. Aggregate formation in tumour microvasculature
continued through light treatment until the vascular lumen was
completely occluded. Constriction of the wall of blood vessels was
not observed during, or acutely after, PDT as found with certain
photosensitizers including Photofrin (Fingar et al, 1992). Similar
effects were found in tumour microvasculature for animals given
light treatment after 30 min BPD incubation. Complete or nearly
complete occlusion of microvasculature in tumour was observed
by the end of the light treatment; however, no pronounced changes
were observed in normal blood vessels in muscle adjacent to the
tumour indicating that selectivity for damage could be obtained at
the 30-min time point. Light treatment 180 min after BPD admin-
istration produced no apparent acute vascular response in either
normal muscle microvasculature or tumour blood vessels.
Although light treatment did not produce acute microvascular
damage and blood flow stasis in tumour, damage to these blood
vessels did progress over the next 24 h and did result in significant
reductions in tissue perfusion as shown by the fluorescein dye
exclusion studies. Progressive damage to tumour microvasculature
after the completion of PDT using BPD has been described by
Levy et al (1993).
These data were confirmed by histology of tissue sections taken
immediately after PDT. Foci of platelet aggregates were observed
in arterioles and venules in animals given light treatment at 5 or 30
min after BPD injection. Likewise, analysis of fluorescein dye
exclusion revealed complete blood flow stasis in treated microvas-
culature immediately after PDT for animals given light 5 min after
BPD injection, but not at the 180-min BPD incubation interval.
The formation of platelet thrombi leading to vessel occlusion
and blood flow stasis after PDT using BPD that was observed in
these studies of tumour microvasculature has been described in
several studies of rabbit eye microvasculature and ocular tumours.
Lin et al (1994) observed the formation of platelet debris and
extravasation of red blood cells in choroidal capillaries after treat-
ment with light within 1 min of BPD injection. The vascular
endothelium was significantly damaged with loss of cellular struc-
ture and the collagen matrix surrounding vessels was disorganized.
Selective thrombosis in corneal vasculature and subretinal vessels
was observed after fluorescein angiography in studies by Schmidt-
Erfurth et al (1994, 1995) using BPD at 180 min. Vascular damage
and ischaemia resulting from endothelial cell damage and platelet
aggregation has also been described in intraocular tumours after
PDT using BPD with incubation times of 15 and 180 min
(Schmidt-Erfurth et al, 1996; Young et al, 1996).
The time course of the vascular photosensitization in the rat
cremaster muscle with chondrosarcoma differed from the data
from the rabbit eye models described by Schmidt-Erfurth et al
(1994, 1995) since we did not observe acute vascular damage in
either normal muscle tissue or in tumour at 180 min. The reasons
for this difference remain unclear but may be related to species
differences in plasma pharmacokinetics or tissue-specific differ-
ences in BPD retention. Overall, the data from our studies and the
previous work in the rabbit models demonstrate that vascular
damage after PDT is greater in animals given light treatment at
short intervals after BPD injection. These data are consistent with
measurements of tissue levels of BPD in highly vascularized struc-
tures of the rabbit eye such as the cilliary body and choroid where
the highest BPD levels were observed 5 min after photosensitizer
injection (Haimovici et al, 1997) and the rapid distribution of BPD
into murine tissues after injection (Richter et al, 1990, 1993).
The selectivity in tumour microvascular response that we
observed after the 30-min BPD incubation period compared to earlier
treatment points is similar to the selectivity observed in rabbit ocular
tissues at 180 min BPD incubation (Schmidt-Erfurth et al, 1994,
1995). This selectivity may be related to the increased accumulation
of BPD by tumour endothelial cells with high levels of low-density
lipoprotein (LDL) receptors (Allison et al, 1994) or the rapid inter-
nalization of agents bound to the LDL receptor on proliferating
endothelial cells compared to quiescent endothelial cells (Fielding et
al, 1979). Cells with increased phagocytotic activity, such as injured
vessel wall in atherosclerotic vessels, have been shown to accumu-
late BPD at levels in excess of surrounding microvasculature
(Allison et al, 1997) and this may play a role in tumour microvascu-
lature as well. Similarly, macrophages show pronounced levels of
BPD uptake compared to other cells and this may also contribute to
the observed effect (Korbelik and Krosl, 1995).
Tumour regression and the degree of surrounding tissue damage
after PDT correlated with the presence or absence of acute vascular
stasis observed in the rat cremaster model. Tissues that exhibited
early vascular stasis and ischaemia showed significant damage
24–48 h after PDT with tissue destruction and eschar formation.
Although initial regression occurred in chondrosarcoma treated
with BPD at all three incubation protocols, including the 180-min
incubation protocol where no initial vascular stasis was observed
during intravital microscopy, the greatest number of animals that
remained tumour-free at 42 days was with the 5-min incubation
protocol. This effect may be related to the absence of tissue selec-
tivity in this treatment protocol and that a margin of normal tissue
must be destroyed to ensure tumour cure (Fingar and Henderson,
1987; Star et al, 1986). The necrosis in the skin surrounding tumour
and the underlying muscle in these animals is apparently due to
tissue ischaemia as predicted by the microvascular studies.
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Figure 4 Tumour response and cure following PDT with BPD.
Sprague–Dawley rats were injected with 2 mg kg-1 BPD i.v. at 5 min, 30 min
or 180 min before light treatment. Light treatment was 150 J cm-2 690 nm to a
1.5 cm diameter spot centred over chondrosarcoma on the right hind limb.
Animals were considered cured of tumour if no regrowth was observed
before 42 days after treatment. (•) Animals given light treatment 5 min after
BPD injection (n = 5), (n) animals given light treatment 30 min after BPD
injection (n = 20), (s) animals given light treatment 180 min after BPD
injection (n = 20)1708 VH Fingar et al
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Significant delays before tumour regrowth were observed in the
animals given light treatment 180 min after BPD injection and this
may be related to the observations of late vascular stasis in animals
treated with this protocol. The timing of tumour regrowth in these
animals is consistent with the presence of surviving nests of tumour
cells after PDT that exist close to the undamaged surrounding
normal tissues and cause regrowth at a later time.
An important conclusion of these studies is that the timing of
light treatment after BPD injection is critical and that the magni-
tude of vascular damage in different tissues can be modulated by
treating at earlier or later times. For tumour destruction, treatment
times can be chosen to balance the relative selectivity of the tissue
ablation. Vessel damage and blood flow stasis is a significant
component of the PDT effect that contributes to tumour regression,
and early treatment times can be chosen to maximize this effect.
These data may have important implications for treatment of non-
cancer applications in which vessel ablation is desired. For treat-
ment of aberrant neovasculature in tissues, including the eye
where selectivity is vital, treatment should be delivered at later
periods after photosensitizer injection where selectivity is
observed rather than treating immediately after BPD administra-
tion. Since the relative clearance and metabolism of BPD varies in
different tissues and in different species, additional investigations
are warranted to identify the timing for optimal vascular sensitivity
in humans.
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